Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin As First-Line Therapy in Type 2 Diabetes

Authors

Patricia Rodriguez
Samuel Gratzl
Ryan Lee
Sarah Gilson
Peter Smits
Nicholas L Stucky, Antimicrobial Stewardship Program, Providence Health and Services, Portland, OR, USA.Follow
Tyler J Gluckman, Center for Cardivascular Analytics, Research and Data Science (CARDS), Providence Heart and Vascular Institute, Providence St. Joseph Health, Portland, OR, USA.Follow

Document Type

Abstract

Publication Date

5-2023

Publication Title

ISPOR—The Professional Society for Health Economics and Outcomes Research Annual Meeting, May 7-10, 2023, Boston, MA

Keywords

oregon; cards; cards presentation

Clinical Institute

Cardiovascular (Heart)

Clinical Institute

Kidney & Diabetes

Department

Center for Cardiovascular Analytics, Research + Data Science (CARDS)

Recommended Citation

Rodriguez, Patricia; Gratzl, Samuel; Lee, Ryan; Gilson, Sarah; Smits, Peter; Stucky, Nicholas L; and Gluckman, Tyler J, "Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin As First-Line Therapy in Type 2 Diabetes" (2023). Articles, Abstracts, and Reports. 7758.
https://digitalcommons.providence.org/publications/7758